Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | REGN5678 |
Synonyms | |
Therapy Description |
REGN5678 is a bispecific antibody that targets prostate-specific membrane antigen (PSMA) and CD28, which may couple T-cells to PSMA-expressing tumor cells, potentially leading to enhanced T-lymphocyte activation and antitumor activity (J Clin Oncol 2021 39:6_suppl, TPS174). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN5678 | REGN 5678|REGN-5678 | PSMA Antibody 20 | REGN5678 is a bispecific antibody that targets prostate-specific membrane antigen (PSMA) and CD28, which may couple T-cells to PSMA-expressing tumor cells, potentially leading to enhanced T-lymphocyte activation and antitumor activity (J Clin Oncol 2021 39:6_suppl, TPS174). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06085664 | Phase Ib/II | REGN5678 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | Recruiting | USA | 0 |